SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000891293-17-000100
Filing Date
2017-09-26
Accepted
2017-09-26 16:54:33
Documents
5
Period of Report
2017-09-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a8-ksept2617.htm 8-K 45637
2 EXHIBIT 4.1 amendmenttorightsplansept2.htm EX-4.1 30881
3 EXHIBIT 10.1 kirskeseverance.htm EX-10.1 65978
4 EXHIBIT 99.1 pressreleasesept26.htm EX-99.1 11691
5 newchairmanandmgmtpro_image1.gif GRAPHIC 2421
  Complete submission text file 0000891293-17-000100.txt   159136
Mailing Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: WA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 171102584
SIC: 2834 Pharmaceutical Preparations